NexgenRx Announces Its 2013 Second Quarter Results

NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) is pleased to
report financial results for its second quarter, ended June 30, 2013.


Revenue from transaction fees for the quarter ended June 30, 2013 was $1,275,764
representing an increase of 18% over the same period in 2012. The gross profit
for the period was $1,046,867, an increase of 29% compared to the same quarter
in 2012.


"The Company achieved positive net income of $230,450 for the quarter. Year to
date, our net income is $492,825, an increase of over $420,000 in comparison to
the same period last year. Cash generated from operating activities is $361,401
during the second quarter, an increase of over $300,000 in comparison to the
same period in 2012. Available cash on hand of $781,789 will enable us to deploy
the funds needed to accelerate our new sales strategy and continue our growth."
stated Ron Loucks, President and CEO.


About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design,
management and administration of health benefit plans offered by employers and
other plan sponsors for the benefit of their employees and plan members. More
information on NexgenRx can be found at www.nexgenrx.com.


Caution Regarding Forward-Looking Statements - This news release contains
certain forward looking statements, including statements regarding the business
and anticipated financial performance of the Corporation. These statements are
subject to a number of risks and uncertainties. Actual results may differ
materially from results contemplated by the forward-looking statements. When
relying on forward-looking statements to make decisions, investors and others
should carefully consider the foregoing factors and other uncertainties and
should not place undue reliance on such forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
NexgenRx Inc.
Ronald C. Loucks
President and CEO
416.695.3393 x801


NexgenRx Inc.
Taba Merrikh
Director of Finance
416-695-3393 x803
www.nexgenrx.com